P Lewczuk, P Riederer, SE O'bryant… - The world journal of …, 2018 - Taylor & Francis
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in …
Introduction We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of …
Background: Diagnostic research criteria for Alzheimer's disease support the use of biomarkers in the cerebrospinal fluid (CSF) to improve the accuracy of the prognosis …
Background Recent developments in blood biomarkers (BBM) have shown promising results in diagnosing amyloid pathology in Alzheimer's Disease (AD). However, information …
Background. Symptoms of functional neurological disorder have traditionally been thought to depend, in part, on patients' ideas about symptoms rather than on the rules of …
E Fernström, K Minta, U Andreasson… - Journal of internal …, 2018 - Wiley Online Library
Background Advances in the treatment of brain tumours have increased the number of long‐ term survivors, but at the cost of side effects following cranial radiotherapy ranging from …
DS Marín-Medina, PA Arenas-Vargas… - Neurology …, 2024 - Elsevier
Introduction Many patients with cognitive symptoms, such as subjective memory complaints, may in fact have functional cognitive disorder. Development This review explores various …
Introduction: The task of discovery and development of novel therapeutic agents remains an expensive, uncertain, time-consuming, competitive, and inefficient enterprise. Due to a …
Introduction A timely diagnosis of Alzheimer's Disease (AD) in an early stage of dementia is important to support timely access to treatment, advice, and care. The aim of this study was …